Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
Note: This is the most current version of the guidelines (June 2013). The March 2014 MMWR notice refers to this version.
(PDF - 492K)
Table of Contents
- Introduction
- Methodology for Preparation of these Guidelines
- The Role of Rifamycins in Tuberculosis Treatment
- Managing Drug Interactions with Antiretrovirals and Rifampin
- Managing Drug Interactions with Antivirals and Rifabutin
- Treatment of Latent TB Infection with Rifampin or Rifapentine
- Treating Pregnant Women with Tuberculosis and HIV Co-infection
- Treating Children with HIV-associated Tuberculosis
- Co-treatment of Multidrug-resistant Tuberculosis and HIV
- Limitations of these Guidelines
- HIV-TB Drug Interaction Guideline Development Group
- References
- Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults
- Table 1b.Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children
- Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults
- Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children
- Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults
- Page last reviewed: December 9, 2013
- Page last updated: September 24, 2012
- Content source: